Achillion Pharmaceuticals, Inc. Nominates ACH-1625 as Lead Candidate in Proprietary Program Targeting HCV Protease

NEW HAVEN, Conn., June 4, 2008 (PRIME NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the nomination of its first clinical candidate from the company’s proprietary HCV protease program. The candidate, ACH-1625, is a highly selective inhibitor of HCV NS3 protease.